Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Herpes Zoster Vaccine in Healthy Adults Aged 30 Years and Above
NCT05856084Phase 2Completed
- Sponsor
- MAXVAX Biotechnology
- Start
- May 2023
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant herpes zoster vaccine (CHO cells) in herpes zoster (HZ), sponsored by MAXVAX Biotechnology. Started May 2023; status: completed.
02
Drugs
recombinant herpes zoster vaccine (CHO cells)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05856084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856084.